<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fondaparinux: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fondaparinux: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fondaparinux: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8691" href="/d/html/8691.html" rel="external">see "Fondaparinux: Drug information"</a> and <a class="drug drug_patient" data-topicid="12496" href="/d/html/12496.html" rel="external">see "Fondaparinux: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708809"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Spinal/Epidural hematomas:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins, heparinoids, or fondaparinux and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants; a history of traumatic or repeated epidural or spinal puncture; or a history of spinal deformity or spinal surgery. Optimal timing between the administration of fondaparinux and neuraxial procedures is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F174015"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Arixtra</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866972"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Arixtra</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1015194"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Factor Xa Inhibitor</span></li></ul></div>
<div class="block dop drugH1Div" id="F53632524"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2e95a9db-43d6-42c1-8cc7-f4ef40a835b7">Deep vein thrombosis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis (DVT), treatment:</b> Limited data available: Children and Adolescents: SubQ: 0.1 mg/kg/dose once daily; dosing based on 2 pediatric studies including a prospective dose-finding, pharmacokinetic, and safety study in patients (n=24, age: 1 to 18 years) receiving primary treatment for DVT (n=23) or heparin-induced thrombocytopenia (n=1) and a consecutive cohort study evaluating long-term safety, dosing, and efficacy (n=35, age: 9.11 ± 0.95 years [range: 1 to 17 years]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25087891','lexi-content-ref-21319285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25087891','lexi-content-ref-21319285'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Dose adjustment for DVT treatment:</b></i> Titrate dose to achieve a 3- to 4-hour postdose target fondaparinux Antifactor Xa level of 0.5 to 1 mg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25087891','lexi-content-ref-21319285','lexi-content-ref-29173784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25087891','lexi-content-ref-21319285','lexi-content-ref-29173784'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Fondaparinux Dose Titration</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Fondaparinux Antifactor Xa Level</p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Dose Titration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Modified from Young G, Lee DL, O'Brien SH et al. FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. <i>Pediatr Blood Cancer. </i>2011;57:1049-1054.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;0.3 mg/L</p></td>
<td align="center">
<p style="text-indent:0em;">Increase dose by 0.03 mg/kg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.3 to 0.49 mg/L</p></td>
<td align="center">
<p style="text-indent:0em;">Increase dose by 0.01 mg/kg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">0.5 to 1 mg/L</p></td>
<td align="center">
<p style="text-indent:0em;">Keep same dosage</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1.1 to 1.2 mg/L</p></td>
<td align="center">
<p style="text-indent:0em;">Decrease dose by 0.01 mg/kg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;1.2 mg/L</p></td>
<td align="center">
<p style="text-indent:0em;">Decrease dose by 0.03 mg/kg</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53632805"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; based on experience in adult patients, dosage adjustments are suggested in mild and moderate renal impairment and fondaparinux is contraindicated in severe renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F53632806"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; based on experience in adult patients, use with caution in severe hepatic impairment and monitor closely for signs and symptoms of bleeding.</p></div>
<div class="block doa drugH1Div" id="F174018"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8691" href="/d/html/8691.html" rel="external">see "Fondaparinux: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Fondaparinux may be used in patients with acute or remote heparin-induced thrombocytopenia (HIT) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-21393394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-21393394'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Non ST-elevation acute coronary syndrome: <b>SUBQ:</b> 2.5 mg once daily; treat for the duration of hospitalization or until percutaneous coronary intervention (PCI) performed. If PCI is performed, an alternative anticoagulant with antithrombin activity (ie, unfractionated heparin) is recommended during the procedure. Fondaparinux as the sole anticoagulant is not recommended during PCI due to an increased risk for guiding-catheter thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">ST-elevation myocardial infarction: IV: 2.5 mg once; subsequent doses (starting the following day): <b>SUBQ:</b> 2.5 mg once daily; treat for the duration of the hospitalization, up to 8 days, or until PCI is performed. If PCI is performed, an alternative anticoagulant with antithrombin activity (ie, unfractionated heparin) is recommended during the procedure. Fondaparinux as the sole anticoagulant is not recommended during PCI due to an increased risk for guiding-catheter thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-23247304','lexi-content-ref-16537725']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-23247304','lexi-content-ref-16537725'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc833446-21e4-4fa4-b4a8-a0ded57b0b93">Deep vein thrombosis and/or pulmonary embolism treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis and/or pulmonary embolism treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For timing of initiating oral anticoagulant, see <b>Transitioning Between Anticoagulants </b>below.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:8em;">&lt;50 kg: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">50 to 100 kg: 7.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;100 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapeutic anticoagulation (first episode, general recommendations):</i> Optimal duration of therapy is unknown and depends on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preference.</p>
<p style="text-indent:-2em;margin-left:8em;">Provoked venous thromboembolism: 3 months (provided the provoking risk factor is no longer present) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Unprovoked venous thromboembolism or provoked venous thromboembolism with a persistent risk factor: ≥3 months depending on risk of venous thromboembolism (VTE) recurrence and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-22332937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-22332937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> All patients receiving indefinite therapeutic anticoagulation with no specified stop date should be reassessed at periodic intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb852ec1-0c11-453d-8407-fe9f495e47e3">Heparin-induced thrombocytopenia treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia treatment (alternative agent) (off-label use): </b>
<b>Note:</b> For initial therapy of acute HIT in selected hemodynamically stable patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482768','lexi-content-ref-19825921','lexi-content-ref-18217156','lexi-content-ref-21883878']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482768','lexi-content-ref-19825921','lexi-content-ref-18217156','lexi-content-ref-21883878'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:6em;">&lt;50 kg: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">50 to 100 kg: 7.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;100 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: Not well established.</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin-induced thrombocytopenia without thrombosis: Typically, 4 weeks to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270'])">Ref</a></span>). Alternatively, may discontinue anticoagulation after platelet count recovery, potentially resulting in a shorter duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Heparin-induced thrombocytopenia with thrombosis: Typically, 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-30482768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ecba0286-174b-43f1-b4e1-06dd8e2abeb8">Superficial vein thrombosis, acute symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Superficial vein thrombosis, acute symptomatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients at increased risk for thromboembolism or with recurrent superficial vein thrombosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 2.5 mg once daily for 45 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-20860504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-20860504'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9a047b1-b986-48a3-abb0-5ccd3dd3f7c9">Venous thromboembolism prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Prophylactic use contraindicated in patients &lt;50 kg. Fondaparinux may be used in patients with a history of HIT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482768','lexi-content-ref-19737996','lexi-content-ref-15339691','lexi-content-ref-14607764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482768','lexi-content-ref-19737996','lexi-content-ref-15339691','lexi-content-ref-14607764'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Medical patients with acute illness at moderate and high risk for venous thromboembolism (off-label use)</i>: <b>SUBQ:</b> 2.5 mg once daily; continue for length of hospital stay or until patient is fully ambulatory and risk of VTE has diminished (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315261','lexi-content-ref-31381464','lexi-content-ref-19737996','lexi-content-ref-16439370','lexi-content-ref-15339691','lexi-content-ref-14607764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315261','lexi-content-ref-31381464','lexi-content-ref-19737996','lexi-content-ref-16439370','lexi-content-ref-15339691','lexi-content-ref-14607764'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Major surgery for cancer (off-label use)</i>: <b>SUBQ:</b> 2.5 mg once daily beginning 6 to 8 hours postoperatively. The optimal duration of prophylaxis has not been established; usually given for a minimum of 7 to 10 days. Extending for up to 4 weeks may be considered in patients undergoing major abdominal or pelvic surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31381464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31381464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical patients (without cancer): </i>
<b>SUBQ:</b> ≥50 kg: 2.5 mg once daily beginning after hemostasis has been established, no earlier than 6 to 8 hours postoperatively.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration</i>
<i>in nonorthopedic surgery</i>: Continue until fully ambulatory and risk of VTE has diminished (typically up to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315263','lexi-content-ref-Douketis.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315263','lexi-content-ref-Douketis.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration in orthopedic surgery</i>: Optimal duration of prophylaxis is unknown, but it is usually given for a minimum of 10 to 14 days and can be extended for up to 35 days; some experts suggest a duration in the lower end of the range (eg, 10 to 14 days) for total knee arthroplasty or higher end of range (eg, ~30 days) for total hip arthroplasty (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265','lexi-content-ref-Pai.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265','lexi-content-ref-Pai.1'])">Ref</a></span>). For extended prophylaxis, may transition to an oral anticoagulant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transitioning between anticoagulants:</b>
<b> Note: </b>This provides general guidance on transitioning between anticoagulants; refer to label and local protocol for additional detail:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transitioning from fondaparinux to another anticoagulant:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from fondaparinux to unfractionated heparin (UFH) continuous infusion:</i> Start maintenance dose (no bolus) of unfractionated heparin 1 to 2 hours prior to when the next dose of fondaparinux is scheduled to be given (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nutescu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nutescu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from fondaparinux to non-warfarin oral anticoagulant (NOAC): </i>Start NOAC within 0 to 2 hours of when the next dose of fondaparinux is scheduled to be given (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26780747','lexi-content-ref-26780745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26780747','lexi-content-ref-26780745'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from fondaparinux to warfarin: </i>Overlap fondaparinux and warfarin until a therapeutic INR has been established. INR should be ≥2 for at least 24 hours and parenteral therapy should be continued for at least 5 days for initial treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315257','lexi-content-ref-26780745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315257','lexi-content-ref-26780745'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transitioning from another anticoagulant to fondaparinux:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from UFH continuous infusion to fondaparinux:</i> Start fondaparinux within one hour after UFH continuous infusion has been stopped (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nutescu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nutescu.1'])">Ref</a></span>) (consult local protocol if aPTT is above the target range).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from NOAC to fondaparinux:</i> Start fondaparinux at the time when the next dose of NOAC would have been given (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Transitioning from warfarin to fondaparinux:</i> Discontinue warfarin and initiate fondaparinux as soon as INR becomes subtherapeutic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990852"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b>
<b>SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 50 to 80 mL/minute: No dosage adjustment necessary. However, total clearance reduced ~25% in patients with CrCl 50 to 80 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 50 mL/minute: No dosage adjustment necessary. However, use with caution and monitor closely for bleeding as accumulation can occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stacy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stacy.1'])">Ref</a></span>); total clearance reduced ~40% compared to patients with CrCl &gt;80 mL/minute. Some experts would consider switching to an alternative anticoagulant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bauer.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bauer.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">When used for thromboprophylaxis, some experts recommend a 50% dose reduction or use of low-dose heparin instead of fondaparinux (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315264'])">Ref</a></span>). Pharmacokinetic simulations and cohort studies suggest a 40% dose reduction (1.5 mg daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22476471','lexi-content-ref-19339838','lexi-content-ref-29877590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22476471','lexi-content-ref-19339838','lexi-content-ref-29877590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Use is contraindicated in the manufacturer's labeling. Total clearance is reduced ~55% compared to patients with CrCl &gt;80 mL/minute.</p>
<p style="text-indent:-2em;margin-left:6em;">Limited data suggest that the use of the 1.5 mg daily dose for thromboprophylaxis in patients with a CrCl of 20 to 50 mL/minute may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22476471','lexi-content-ref-19339838','lexi-content-ref-29877590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22476471','lexi-content-ref-19339838','lexi-content-ref-29877590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b>
<b>SUBQ:</b> Avoid use. Although clearance may actually increase by 20% in patients receiving chronic intermittent hemodialysis, fondaparinux may accumulate (as shown by rising anti-Xa levels) with repeated dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18064314','lexi-content-ref-18397694','lexi-content-ref-24021678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18064314','lexi-content-ref-18397694','lexi-content-ref-24021678'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>SUBQ:</b> Avoid use. Unlikely to be substantially cleared by peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988124"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate impairment (Child-Pugh class A and B): No dosage adjustment necessary; monitor for signs of bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustment provided in the manufacturer's labeling (has not been studied). Use with caution; monitor closely for signs of bleeding.</p></div>
<div class="block adr drugH1Div" id="F173981"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As with all anticoagulants, bleeding is the major adverse effect. Hemorrhage may occur at any site. Risk appears increased by a number of factors including renal dysfunction, age (&gt;75 years), and weight (&lt;50 kg).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hematologic &amp; oncologic: Anemia (2% to 20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Insomnia (≤5%), dizziness (≤4%), confusion (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Increased wound secretion (≤5%), skin blister (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Purpura (≤4%), thrombocytopenia (50,000 to 100,000/mm<sup>3</sup>: 3%), hematoma (2% to 3%), minor hemorrhage (2% to 3%), major hemorrhage (1% to 3%; risk of major hemorrhage increased as high as 5% in patients receiving initial dose &lt;6 hours following surgery), postoperative hemorrhage (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT (&gt;3 × ULN: 1% to 3%), increased serum AST (&gt;3 × ULN: &lt;1% to ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: postoperative wound infection (abdominal surgery: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (VTE: 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, angioedema, catheter site thrombosis (during PCI; without heparin), elevated aPTT associated with bleeding, epidural hematoma, hemorrhagic death, injection site reaction (bleeding at injection site, skin rash, pruritus), intracranial hemorrhage, reoperation due to bleeding, severe thrombocytopenia (&lt;50,000/mm<sup>3</sup>), spinal hematoma, thrombocytopenia (with thrombosis)</p></div>
<div class="block coi drugH1Div" id="F173997"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity (eg, angioedema, anaphylactoid/anaphylactic reactions) to fondaparinux or any component of the formulation; severe renal impairment (CrCl &lt;30 mL/minute); body weight &lt;50 kg (prophylaxis); active major bleeding; bacterial endocarditis; thrombocytopenia associated with a positive <i>in vitro</i> test for antiplatelet antibody in the presence of fondaparinux</p></div>
<div class="block war drugH1Div" id="F173979"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative and angiodysplastic GI disease; uncontrolled arterial hypertension; hemorrhagic stroke; recent intracranial hemorrhage; use shortly after brain, spinal, or ophthalmology surgery; in patients treated concomitantly with platelet inhibitors; thrombocytopenia or platelet defects; renal impairment; diabetic retinopathy; and/or patients &lt;50 kg. Risk of major bleeding may be increased if initial dose is administered earlier than recommended (initiation recommended at 6 to 8 hours following surgery). Do not administer with other agents that increase the risk of hemorrhage unless they are essential for the management of the underlying condition (eg, vitamin K antagonists for treatment of venous thromboembolism). Prothrombin time and activated partial thromboplastin time (aPTT) are insensitive measures of fondaparinux activity. If unexpected changes in coagulation parameters or major bleeding occur, discontinue fondaparinux (elevated aPTT associated with bleeding events have been reported in postmarketing data). No specific antidote for fondaparinux exists.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Has occurred with administration, including very rare reports of thrombocytopenia with thrombosis similar to heparin-induced thrombocytopenia (HIT); however, has been used in patients with current or history of HIT due to a lack of an immune-mediated effect on platelets (ACCP [Guyatt 2012]; Savi 2005). Use is contraindicated in patients with thrombocytopenia associated with a positive in vitro test for antiplatelet antibodies in the presence of fondaparinux. Monitor patients closely and discontinue therapy if platelets fall to &lt;100,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: May increase the risk of bleeding in patients with hepatic impairment. Use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: May increase the risk of bleeding in patients with renal impairment. Use with caution in patients with CrCl 30 to 50 mL/minute (may cause prolonged anticoagulation); contraindicated in patients with CrCl &lt;30 mL/minute. Periodically monitor renal function; discontinue immediately if severe renal impairment develops.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; increased risk of bleeding in patients &gt;75 years of age.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients &lt;50 kg: In patients &lt;50 kg, clearance of fondaparinux is reduced by 30% and the risk of bleeding is increased; use is contraindicated in patients &lt;50 kg when used as prophylactic therapy for patients undergoing hip fracture, hip replacement, or knee replacement surgery, or abdominal surgery; use with caution in the treatment of pulmonary embolism and deep vein thrombosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The needle guard may contain natural latex rubber.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For subcutaneous administration; not for IM administration. For ST-elevation myocardial infarction patients (off-label use) may administer initial dose IV. Do not use interchangeably (unit for unit) with low molecular weight heparins, heparin, or heparinoids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation: Following discontinuation, the anticoagulant effects of fondaparinux may persist for 2 to 4 days and even longer in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuraxial anesthesia:<b> [US Boxed Warning]: Spinal or epidural hematomas, including subsequent long-term or permanent paralysis, may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients anticoagulated with l<b>
<b>ow-molecular-weight heparin,</b></b> heparinoids, or fondaparinux.</b>
<b>Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis (such as nonsteroidal anti-inflammatory drugs, platelet inhibitors, or other anticoagulants), the use of indwelling epidural catheters, a history of spinal deformity or spinal surgery, as well as a history of traumatic or repeated epidural or spinal punctures.</b>
<b>Optimal timing between administration of fondaparinux and neuraxial procedures is not known. <b>Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary. Consider the benefit and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Percutaneous coronary intervention: The administration of fondaparinux as the sole anticoagulant is <b>not recommended</b> during percutaneous coronary intervention (PCI) due to an increased risk for guiding-catheter thrombosis. Use of an anticoagulant with antithrombin activity (eg, unfractionated heparin) is recommended as adjunctive therapy to PCI even if prior treatment with fondaparinux (must take into account whether GP IIb/IIIa antagonists have been administered) (ACC/AHA [Lawton 2022]).</p></div>
<div class="block foc drugH1Div" id="F173990"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.4 mL (0.4 mL); 7.5 mg/0.6 mL (0.6 mL); 10 mg/0.8 mL (0.8 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arixtra: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.4 mL (0.4 mL); 7.5 mg/0.6 mL (0.6 mL); 10 mg/0.8 mL (0.8 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/0.5 mL (0.5 mL); 5 mg/0.4 mL (0.4 mL); 7.5 mg/0.6 mL (0.6 mL); 10 mg/0.8 mL (0.8 mL)</p></div>
<div class="block geq drugH1Div" id="F173976"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422230"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Arixtra Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/0.5 mL (per 0.5 mL): $66.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/0.4 mL (per 0.4 mL): $157.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg/0.6 mL (per 0.6 mL): $157.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.8 mL (per 0.8 mL): $157.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fondaparinux Sodium Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/0.5 mL (per 0.5 mL): $14.70 - $57.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/0.4 mL (per 0.4 mL): $42.12 - $135.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg/0.6 mL (per 0.6 mL): $35.10 - $135.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/0.8 mL (per 0.8 mL): $42.12 - $135.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866973"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arixtra: 2.5 mg/0.5 mL (0.5 mL); 7.5 mg/0.6 mL (0.6 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/0.5 mL (0.5 mL); 7.5 mg/0.6 mL (0.6 mL)</p></div>
<div class="block admp drugH1Div" id="F53632807"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: SubQ: For SubQ administration; do <b>not</b> administer IM. In adults, it is recommended to alternate between the left or right anterolateral and left or right posterolateral abdominal wall. Do not expel air bubble from commercial prefilled syringe prior injection.</p></div>
<div class="block adm drugH1Div" id="F173994"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> For SUBQ administration; do <b>not</b> administer IM. Alternate injection sites. Do not expel air bubble from syringe before injection. Administer according to recommended regimen; when used for DVT prophylaxis, early initiation (before 6 hours after orthopedic surgery) has been associated with increased bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For STEMI patients (off-label use) may administer initial dose as IV push or mix in NS and infuse over 1 to 2 minutes; flush tubing with NS after infusion to ensure complete administration for fondaparinux.</p></div>
<div class="block sts drugH1Div" id="F174008"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). For IV infusion (off-label route), use immediately once diluted in NS; can also be stored for up to 24 hours at 15°C to 30°C (59°F to 86°F) (Arixtra Canadian product labeling).</p></div>
<div class="block usep drugH1Div" id="F53566997"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prophylaxis of deep vein thrombosis (DVT) in patients undergoing surgery for hip replacement, knee replacement, hip fracture (including extended prophylaxis following hip fracture surgery), or abdominal surgery (in patients at risk for thromboembolic complications); treatment of acute pulmonary embolism (PE) in conjunction with warfarin; treatment of acute DVT in conjunction with warfarin (All indications: FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F5174539"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arixtra may be confused with Aristada, Arista AH (hemostatic device)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299363"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F173983"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with other anticoagulants prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F173999"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on case reports, small amounts of fondaparinux have been detected in the umbilical cord following multiple doses during pregnancy (Dempfle 2004). Use of fondaparinux in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt 2012).</p></div>
<div class="block mopp drugH1Div" id="F53566996"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic monitoring of CBC with platelets, serum creatinine, occult blood testing of stools, antifactor Xa activity with fondaparinux as the calibrator, signs and symptoms of bleeding. <b>Note:</b> PT and aPTT are insensitive measures of fondaparinux activity.</p></div>
<div class="block rerp drugH1Div" id="F53777461"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Fondaparinux-based Antifactor Xa: <b>Note:</b> The following are suggested peak values of antifactor Xa.</p>
<p style="text-indent:-2em;margin-left:4em;">Therapeutic:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: 0.5 to 1.0 mg/L, measured 3 to 4 hours after SubQ administration (Young 2011).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Acute deep vein thrombosis/pulmonary embolism treatment: 1.2 to 1.26 mg/L (Young 2011, manufacturer labeling).</p></div>
<div class="block pha drugH1Div" id="F173978"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fondaparinux is a synthetic pentasaccharide that causes an antithrombin III-mediated selective inhibition of factor Xa. Neutralization of factor Xa interrupts the blood coagulation cascade and inhibits thrombin formation and thrombus development.</p></div>
<div class="block phk drugH1Div" id="F173996"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: SubQ: Rapid and complete </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 7 to 11 L; mainly in blood </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ≥94% to antithrombin III </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: SubQ: 100% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 17 to 21 hours; prolonged with renal impairment and in the elderly</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: SubQ: ~2 to 3 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (up to 77%, unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51192649"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination is prolonged.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with moderate hepatic impairment (Child-Pugh class B), C<sub>max</sub> and AUC were decreased by 22% and 39%, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elimination is prolonged in patients older than 75 years.</p>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Total clearance is decreased approximately 30% in patients weighing less than 50 kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F174000"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arixtra | Fondaparinux natrium beta</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Arixtra | Diviti</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Arixtra | Fondakem | Fondalin | Fondared</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arixtra</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Arixtra (fondaparinux) [prescribing information]. Morgantown, WV: Mylan Institutional LLC; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arixtra.1">
<a name="Arixtra.1"></a>Arixtra (fondaparinux) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332937">
<a name="22332937"></a>Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2012;10(4):698-702. doi:10.1111/j.1538-7836.2012.04662.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22332937/pubmed" id="22332937" target="_blank">22332937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11794149">
<a name="11794149"></a>Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux Compared With Enoxaparin for the Prevention of Venous Thromboembolism After Elective Major Knee Surgery. <i>N Engl J Med.</i> 2001;345:1305-1310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/11794149/pubmed" id="11794149" target="_blank">11794149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bauer.1">
<a name="Bauer.1"></a>Bauer KA. Fondaparinux Sodium: A Selective Inhibitor of Factor Xa. <i>Am J Health Syst Pharm.</i> 2001;58(suppl 2):14-17.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bauer.2">
<a name="Bauer.2"></a>Bauer K. Fondaparinux: Dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19737996">
<a name="19737996"></a>Blackmer AB, Oertel MD, Valgus JM. Fondaparinux and the Management of Heparin-induced Thrombocytopenia: The Journey Continues. <i>Ann Pharmacother.</i> 2009;43(10):1636-1646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/19737996/pubmed" id="19737996" target="_blank">19737996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15172900">
<a name="15172900"></a>Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis: A Randomized Trial. <i>Ann Intern Med.</i> 2004;140(11):867-873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/15172900/pubmed" id="15172900" target="_blank">15172900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14585937">
<a name="14585937"></a>Buller HR, Davidson BL, Decousus H, et al. Subcutaneous Fondaparinux Versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism. <i>N Engl J Med.</i> 2003;349(18):1695-1702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/14585937/pubmed" id="14585937" target="_blank">14585937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26780747">
<a name="26780747"></a>Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. <i>J Thromb Thrombolysis.</i> 2016;41(1):206-232. doi:10.1007/s11239-015-1310-1317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/26780747/pubmed" id="26780747" target="_blank">26780747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16439370">
<a name="16439370"></a>Cohen AT, Davidson BL, Gallus AS, et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. <i>BMJ.</i> 2006;332(7537):325-329. doi:10.1136/bmj.38733.466748.7C<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/16439370/pubmed" id="16439370" target="_blank">16439370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482768">
<a name="30482768"></a>Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Adv</i>. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/30482768/pubmed" id="30482768" target="_blank">30482768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17403087">
<a name="17403087"></a>Davidson BL, Büller HR, Decousus H, et al; Matisse Investigators. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. <i>J Thromb Haemost</i>. 2007;5(6):1191-1194. doi:10.1111/j.1538-7836.2007.02565.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/17403087/pubmed" id="17403087" target="_blank">17403087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20860504">
<a name="20860504"></a>Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. <i>N Engl J Med.</i> 2010;363(13):1222-1232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/20860504/pubmed" id="20860504" target="_blank">20860504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20539905">
<a name="20539905"></a>Delavenne X, Zufferey P, Baylot D, et al; GETHCAM Study Group; POP-A-RIX Investigators. Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. <i>Thromb Haemost.</i> 2010;104(2):252-260. doi:10.1160/TH10-02-0127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/20539905/pubmed" id="20539905" target="_blank">20539905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15115845">
<a name="15115845"></a>Dempfle CE. Minor Transplacental Passage of Fondaparinux <i>in vivo.</i>
<i>N Engl J Med.</i> 2004;350(18):1914-1915.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/15115845/pubmed" id="15115845" target="_blank">15115845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Douketis.1">
<a name="Douketis.1"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 21, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.1">
<a name="Pai.1"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11794148">
<a name="11794148"></a>Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux Compared With Enoxaparin for the Prevention of Venous Thromboembolism After Hip-Fracture Surgery. <i>N Engl J Med. </i> 2001;345:1298-1304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/11794148/pubmed" id="11794148" target="_blank">11794148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315265">
<a name="22315265"></a>Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):e278S-e325S. doi:10.1378/chest.11-2404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22315265/pubmed" id="22315265" target="_blank">22315265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315264">
<a name="22315264"></a>Garcia DA, Baglin TP, Weitz JI, et al. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest. </i>2012;141(2)(suppl):24-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22315264/pubmed" id="22315264" target="_blank">22315264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883881">
<a name="21883881"></a>Goldfarb MJ, Blostein MD. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. <i>J Thromb Haemost.</i> 2011;9(12):2501-2503. doi:10.1111/j.1538-7836.2011.04489.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/21883881/pubmed" id="21883881" target="_blank">21883881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315263">
<a name="22315263"></a>Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in <i>Chest</i>. 2012;141(5):1369]. <i>Chest</i>. 2012;141(2)(suppl):e227S-e277S. doi:10.1378/chest.11-2297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22315263/pubmed" id="22315263" target="_blank">22315263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19825921">
<a name="19825921"></a>Grouzi E, Kyriakou E, Panagou I, et al. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.<i> Clin Appl Thromb Hemost.</i> 2010;16(6):663-667. doi:10.1177/1076029609347900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/19825921/pubmed" id="19825921" target="_blank">19825921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15339691">
<a name="15339691"></a>Harenberg J, Jorg I, Fenyvesi T. Treatment of Heparin-induced Thrombocytopenia With Fondaparinux. <i>Haematologica. </i>2004;89(8):1017-1018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/15339691/pubmed" id="15339691" target="_blank">15339691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315261">
<a name="22315261"></a>Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):e195S-e226S. doi:10.1378/chest.11-2296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22315261/pubmed" id="22315261" target="_blank">22315261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18064314">
<a name="18064314"></a>Kalicki RM, Aregger F, Alberio L, Lämmle B, Frey FJ, Uehlinger DE. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. <i>Thromb Haemost</i>. 2007;98(6):1200‐1207. doi:10.1160/th07-07-0444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/18064314/pubmed" id="18064314" target="_blank">18064314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25515959">
<a name="25515959"></a>Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study.<i> Blood.</i> 2015;125(6):924-929. doi:10.1182/blood-2014-09-599498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/25515959/pubmed" id="25515959" target="_blank">25515959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest.</i> 2012;141(2)(suppl):e419S-e496S. doi:10.1378/chest.11-2301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in <i>Chest</i>. 2016;150(4):988]. <i>Chest</i>. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381464">
<a name="31381464"></a>Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2020;38(5):496-520. doi:10.1200/JCO.19.01461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/31381464/pubmed" id="31381464" target="_blank">31381464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25087891">
<a name="25087891"></a>Ko RH, Michieli C, Lira JL, Young G. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. <i>Thromb Res</i>. 2014;134(3):643-647.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/25087891/pubmed" id="25087891" target="_blank">25087891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines.<i> J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315270">
<a name="22315270"></a>Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in <i> Chest</i> . 2015;148(6):1529]. <i>Chest</i>. 2012;141(2)(suppl):e495S-e530S. doi:10.1378/chest.11-2303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22315270/pubmed" id="22315270" target="_blank">22315270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18217156">
<a name="18217156"></a>Lobo B, Finch C, Howard A, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.<i> Thromb Haemost.</i> 2008;99(1):208-214. doi:10.1160/TH07-04-0252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/18217156/pubmed" id="18217156" target="_blank">18217156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880887">
<a name="21880887"></a>Martinez L, Burnett A, Borrego M, Streeter JC, Townsend K, Garcia D. Effect of fondaparinux prophylaxis on anti-factor Xa concentrations in patients with morbid obesity. <i>Am J Health Syst Pharm</i>. 2011;68(18):1716-1722. doi:10.2146/ajhp110010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/21880887/pubmed" id="21880887" target="_blank">21880887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22476471">
<a name="22476471"></a>Mismetti P, Samama CM, Rosencher N, et al. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study. <i>Thromb Haemost</i>. 2012;107(6):1151‐1160. doi:10.1160/TH11-09-0640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/22476471/pubmed" id="22476471" target="_blank">22476471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nutescu.1">
<a name="Nutescu.1"></a>Nutescu EA, Dager W. Heparin, Low Molecular Weight Heparin, and Fondaparinux. <i>Managing Anticoagulation Patients in the Hospital. </i>Gulseth M ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:181.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14607764">
<a name="14607764"></a>Parody R, Oliver A, Souto JC, et al. Fondaparinux (Arixtra®), as an Alternative Antithrombotic Prophylaxis When There is Hypersensitivity to Low Molecular Weight and Unfractionated Heparins. <i>Haematologica.</i> 2003;88(11):ECR32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/14607764/pubmed" id="14607764" target="_blank">14607764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29509886">
<a name="29509886"></a>Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>Eur Heart J</i>. 2018;39(19):1672-1686f. doi:10.1093/eurheartj/ehy066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/29509886/pubmed" id="29509886" target="_blank">29509886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15388575">
<a name="15388575"></a>Savi P, Chong BH, Greinacher A, et al. Effect of Fondaparinux on Platelet Activation in the Presence of Heparin-Dependent Antibodies: A Blinded Comparative Multicenter Study With Unfractionated Heparin. <i>Blood.</i> 2005;105(1):139-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/15388575/pubmed" id="15388575" target="_blank">15388575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29169470">
<a name="29169470"></a>Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia.<i> J Am Coll Cardiol.</i> 2017;70(21):2636-2648. doi:10.1016/j.jacc.2017.09.1099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/29169470/pubmed" id="29169470" target="_blank">29169470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482763">
<a name="30482763"></a>Schünemann HJ, Cushman M, Burnett AE, et al . American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. <i>Blood Adv</i>. 2018;2(22):3198-3225. doi:10.1182/bloodadvances.2018022954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/30482763/pubmed" id="30482763" target="_blank">30482763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26780745">
<a name="26780745"></a>Smythe MA, Priziola J, Dobesh PP, et al. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. <i>J Thromb Thrombolysis.</i> 2016;41(1):165-186. doi:10.1007/s11239-015-1315-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/26780745/pubmed" id="26780745" target="_blank">26780745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18397694">
<a name="18397694"></a>Sombolos KI, Fragia TK, Gionanlis LC, et al. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. <i>Int J Clin Pharmacol Ther</i>. 2008;46(4):198‐203. doi:10.5414/cpp46198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/18397694/pubmed" id="18397694" target="_blank">18397694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24021678">
<a name="24021678"></a>Speeckaert MM, Devreese KM, Vanholder RC, Dhondt A. Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients. <i>Nephrol Dial Transplant</i>. 2013;28(12):3090‐3095. doi:10.1093/ndt/gft293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/24021678/pubmed" id="24021678" target="_blank">24021678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stacy.1">
<a name="Stacy.1"></a>Stacy Z, Richter S. Low Molecular Weight Heparin and Fondaparinux. <i>Anticoagulation Therapy: A Clinical Practice Guideline. </i>2nd ed. Dager WE, Gulseth MP, Nutescu EA, eds. American Society of Health-System Pharmacists; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25620436">
<a name="25620436"></a>Steele KE, Canner J, Prokopowicz G, et al. The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. <i>Surg Obes Relat Dis</i>. 2015;11(3):672-683. doi:10.1016/j.soard.2014.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/25620436/pubmed" id="25620436" target="_blank">25620436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19339838">
<a name="19339838"></a>Turpie AG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. <i>Blood Coagul Fibrinolysis</i>. 2009;20(2):114‐121. doi:10.1097/MBC.0b013e328323da86<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/19339838/pubmed" id="19339838" target="_blank">19339838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21393394">
<a name="21393394"></a>Warkentin TE, Davidson BL, Buller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. <i>Chest.</i> 2011a;140(2):366-373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/21393394/pubmed" id="21393394" target="_blank">21393394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17582083">
<a name="17582083"></a>Warkentin TE, Maurer BT, Aster RH. Heparin-Induced Thrombocytopenia Associated With Fondaparinux. <i>N Engl J Med.</i> 2007;356(25):2653-2655.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/17582083/pubmed" id="17582083" target="_blank">17582083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883878">
<a name="21883878"></a>Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. <i>J Thromb Haemost.</i> 2011b;9(12):2389-2396. doi:10.1111/j.1538-7836.2011.04487.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/21883878/pubmed" id="21883878" target="_blank">21883878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29173784">
<a name="29173784"></a>Young G. Anticoagulation therapies in children. <i>Pediatr Clin North Am</i>. 2017;64(6):1257-1269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/29173784/pubmed" id="29173784" target="_blank">29173784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21319285">
<a name="21319285"></a>Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. <i>Pediatr Blood Cancer</i>. 2011;57(6):1049-1054.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/21319285/pubmed" id="21319285" target="_blank">21319285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16537663">
<a name="16537663"></a>Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes − The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. <i>N Engl J Med.</i> 2006a;354(14):1464-1476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/16537663/pubmed" id="16537663" target="_blank">16537663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16537725">
<a name="16537725"></a>Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial. <i>JAMA.</i> 2006b;295(13):1519-1530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/16537725/pubmed" id="16537725" target="_blank">16537725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29877590">
<a name="29877590"></a>Zufferey PJ, Ollier E, Delavenne X, Laporte S, Mismetti P, Duffull SB. Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis. <i>Br J Clin Pharmacol</i>. 2018;84(10):2242‐2251. doi:10.1111/bcp.13663<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fondaparinux-pediatric-drug-information/abstract-text/29877590/pubmed" id="29877590" target="_blank">29877590</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 122584 Version 122.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
